Your need: to analyze and understand DNA and RNA nanopore sequencing to optimize your biopharmaceutical processes
Nanopore sequencing: a cutting-edge technology for biopharmaceuticals
Nanopore sequencing (Qubit) is a next-generation sequencing technology that enables the direct, real-time analysis of DNA and RNA. In the biopharmaceutical industry, it is a strategic tool for characterizing, controlling, and securing biomolecules throughout their lifecycle.
At the filab laboratory, nanopore sequencing is implemented to meet the high demands of the biopharmaceutical industry: data reliability, rapid analysis, expert interpretation, and technical support.
The principle of nanopore sequencing
The technology relies on the passage of a strand of DNA or RNA through a biological or synthetic nanopore. Each nucleotide specifically disrupts the ionic current flowing through the nanopore.
These variations in the electrical signal are continuously recorded and translated into a nucleotide sequence, allowing for long-term reading without mandatory amplification and real-time analysis.
Applications of nanopore sequencing in biopharmaceuticals
This technology is used in numerous industrial contexts:
- Genetic characterization of biomolecules
- Identity and sequence integrity verification
- Detection of variants, mutations, or recombinations
- Analysis of messenger RNA (mRNA)
- Verification of viral and plasmid vectors
- Detection of biological contamination
- Support for R&D studies and analytical development
- Genetic stability studies
FILAB performs nanopore sequencing of your DNA and RNA using cutting-edge resourcies
Expertise in biopharmaceutical matrices
When should nanopore sequencing be used?
Manufacturers are using this technology particularly for:
Securing biopharmaceutical development
Compare batches or lines
Investigating a genetic nonconformity
To meet a regulatory requirement
FAQ
Nanopore sequencing is distinguished by its ability to read long sequences, providing a complete and continuous view of the analyzed DNA or RNA. This extended readout allows for the precise identification of rearrangements, complex variants, or repetitive regions, which are often difficult to characterize with more conventional sequencing technologies.
The technology also enables real-time analysis. Data is generated and usable from the very beginning of the sequencing process, significantly reducing turnaround time and facilitating rapid decision-making in demanding industrial environments.
Another major advantage lies in the direct access to epigenetic modifications, such as methylations, without any additional processing steps. This capability is particularly relevant for the detailed characterization of biomolecules and the monitoring of biopharmaceutical processes.
Furthermore, nanopore sequencing minimizes analytical biases due to the absence, or significant reduction, of amplification steps. The analyzed sequences are thus more representative of the actual sample, enhancing the reliability and robustness of the results.
Finally, this technology offers great flexibility in application, for both DNA and RNA analysis. It integrates seamlessly into a variety of contexts, ranging from quality control to analytical development, including R&D and innovation projects.
These characteristics make nanopore sequencing a tool particularly well-suited to the challenges of controlling, developing, and ensuring the safety of biopharmaceutical products.
Yes. Nanopore sequencing can be implemented within a framework that complies with the regulatory requirements of the biopharmaceutical sector. Protocols are defined, controlled, and documented, with complete traceability of samples, analytical parameters, and generated data. The results can therefore be used in quality, control, or development contexts, in accordance with applicable standards.
The reliability of nanopore sequencing depends on mastering the entire analytical chain: sample preparation, sequencing conditions, bioinformatics processing, and data interpretation. When properly implemented, the technology yields robust, reproducible, and representative data, even for long or complex sequences.
Yes, particularly for identity verification, sequence integrity, or non-conformity investigation. Its speed, flexibility, and ability to provide detailed information make it a relevant tool to support quality decisions in an industrial environment.
